Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Western blot analysis of ERK phosphorylation in HUVECs stimulated for 10 min with AGR2 coupled with or without FGF/VEGF. The concentration of AGR2 is 500 ng/ml. The concentration of VEGF is 5 ng/ml. PD173074: FGFR inhibitor; Axitinib: VEGFR inhibitor (2 nm); BEV: VEGF antibody bevacizumab (5 μg/ml). Quantification of ERK activity was performed by normalizing phosphorylated ERK to β-actin, untreated control (lane 1) was set to 1. All data represent four independent biological replicates and shown as means±s.d. Asterisks indicate significant differences (*, Pless than or equal to0.05; **, Pless than or equal to0.01).

    Oncogene, 2017. Axitinib purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

  • Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NXuxflNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rkRWlEPTB;MD6wNFAxPTF|IN88US=> NVfv[GRSW0GQR1XS
NCI-H1703 NFvRbVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMECwPVAzKM7:TR?= MVPTRW5ITVJ?
KASUMI-1 NWSzeIVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTyPWNiUUN3ME2wMlAxPjh{IN88US=> MknnV2FPT0WU
CGTH-W-1 NFruSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XVbWlEPTB;MD6wNFczOiEQvF2= NV72XndIW0GQR1XS
A204 NUGxR4lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L0R2lEPTB;MD6wNFk6OiEQvF2= NFTlN5dUSU6JRWK=
HOP-62 NXXDZY5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm0TWM2OD1yLkGwPFM3KM7:TR?= NIPDW2lUSU6JRWK=
H-EMC-SS Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\UOW1KSzVyPUCuNVExODVizszN NVj4VVBTW0GQR1XS
KU812 Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnnflFKSzVyPUCuNVY2PzdizszN MmT2V2FPT0WU
EM-2 NUTjb3Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnLVWp2UUN3ME2wMlE3QDF4IN88US=> NV;B[XRCW0GQR1XS
LAMA-84 M2fl[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT6ToJKSzVyPUCuNVc3PjVizszN MVrTRW5ITVJ?
JAR M4HWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXSbIFKSzVyPUCuNlM6QDlizszN MlHFV2FPT0WU
G-361 Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTaTWM2OD1yLkOyN|I2KM7:TR?= NEHRXVhUSU6JRWK=
KG-1 M{DHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT3[4pKSzVyPUCuN|c3PDJizszN Mkn0V2FPT0WU
BV-173 Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;5U3BDUUN3ME2wMlM6OzJizszN MX3TRW5ITVJ?
K5 M{DqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW0OZZKSzVyPUCuOFIyOjdizszN NFrlZnlUSU6JRWK=
MEG-01 M1fBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwNEKzOlEh|ryP MYLTRW5ITVJ?
MFM-223 NGTTUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrOcHNKSzVyPUCuOFQ4PzZizszN NHPiUlFUSU6JRWK=
BE-13 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke3TWM2OD1yLkWxNFA5KM7:TR?= NVyzNGRiW0GQR1XS
NEC8 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDSTWM2OD1yLkeyNVE{KM7:TR?= NHz6T25USU6JRWK=
SW756 NXm4PVBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zZNmlEPTB;MD65PVg1PiEQvF2= MX;TRW5ITVJ?
A2780 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjOTWM2OD1zLkCxNVQ3KM7:TR?= Ml7ZV2FPT0WU
NB14 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHGxcG1KSzVyPUGuNFE5ODFizszN M1uxWnNCVkeHUh?=
H4 NIjoVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTROGVoUUN3ME2xMlA3PDJ{IN88US=> M3XNPXNCVkeHUh?=
SK-OV-3 NET6NIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3RTWM2OD1zLkC2OlM{KM7:TR?= M3rDXXNCVkeHUh?=
AN3-CA M1OyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfYTWM2OD1zLkC4N|g6KM7:TR?= M2P4VnNCVkeHUh?=
A427 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvxTWM2OD1zLkGwN|gyKM7:TR?= MWDTRW5ITVJ?
ES7 NVzubpFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf2TWM2OD1zLkGxN|M1KM7:TR?= NUP4N5NpW0GQR1XS
AGS MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrGVG1xUUN3ME2xMlEyOzl3IN88US=> MnSyV2FPT0WU
G-402 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwMUS2PVQh|ryP MorGV2FPT0WU
ES5 NW\YOnZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWqxenFoUUN3ME2xMlE4OjR6IN88US=> MkToV2FPT0WU
DEL NXPXeY9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwMkW0OVch|ryP NU[1N4FIW0GQR1XS
NB10 MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\Nb2lEPTB;MT6zNlU2PyEQvF2= MoPHV2FPT0WU
NCI-H1581 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP3d|ZKSzVyPUGuN|kxPDJizszN MXnTRW5ITVJ?
D-566MG NGny[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrxd|NKSzVyPUGuOFA3QDNizszN M372SXNCVkeHUh?=
LXF-289 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPYTWM2OD1zLkSzPVk3KM7:TR?= NFLKe4NUSU6JRWK=
BT-549 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\5XWlEPTB;MT61OlkxQSEQvF2= M2fNPHNCVkeHUh?=
NKM-1 M2S2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLBUlZKSzVyPUGuOlA2PTZizszN NGDSTmhUSU6JRWK=
SW780 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrafWRxUUN3ME2xMlY2OTV6IN88US=> NXnleZlbW0GQR1XS
NCI-H292 NYrpeIlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHWzXG1KSzVyPUGuOlY{QDNizszN MV7TRW5ITVJ?
HMV-II Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\HTWM2OD1zLkewOFg5KM7:TR?= M1\hVXNCVkeHUh?=
ALL-PO M4fFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fQZ2lEPTB;MT64NFAyPSEQvF2= NHT4eVlUSU6JRWK=
UACC-257 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFwOEKxOlMh|ryP MlH3V2FPT0WU
PA-1 NXu2foZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFwOEK3NlUh|ryP M3vPZnNCVkeHUh?=
HD-MY-Z MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwOE[yPFEh|ryP NHPzR5VUSU6JRWK=
HSC-4 Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwOUO4N|kh|ryP MWXTRW5ITVJ?
GCT M4PNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\jOWlEPTB;Mj6wNFkyPiEQvF2= NYrkb5B2W0GQR1XS
RT-112 NGTMO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr0TWM2OD1{LkGzOFI1KM7:TR?= M4jhRnNCVkeHUh?=
A172 M1roUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvUfo9KSzVyPUKuNVM3ODZizszN NVm0bWZ1W0GQR1XS
HCE-T MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe0OVNbUUN3ME2yMlIxPTl6IN88US=> NELDXWJUSU6JRWK=
YH-13 NEG3R4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rsXmlEPTB;Mj6yNVY4OSEQvF2= MWXTRW5ITVJ?
DK-MG M2G2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF34PJlKSzVyPUKuNlM5OzRizszN MVzTRW5ITVJ?
ACN MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJwMkO4O|Uh|ryP MmDiV2FPT0WU
VA-ES-BJ NHrV[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XCfmlEPTB;Mj6yOFk2PyEQvF2= NWnVZ2dWW0GQR1XS
L-363 M{nCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37QcGlEPTB;Mj6yPFA3OSEQvF2= MmS2V2FPT0WU
HuH-7 M2DrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jLSmlEPTB;Mj60NlE3PSEQvF2= M33sOnNCVkeHUh?=
A4-Fuk M1y5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXUTWM2OD1{LkS3NVY5KM7:TR?= NEnHUWtUSU6JRWK=
T-24 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\6TWlEPTB;Mj60PFA{PyEQvF2= MlLSV2FPT0WU
GOTO MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwNUOwNVMh|ryP MUTTRW5ITVJ?
MV-4-11 NVLObFVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\BNmlEPTB;Mj61PVE3QSEQvF2= M1;weXNCVkeHUh?=
DMS-114 M{XLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHYTWM2OD1{Lk[2N|Q2KM7:TR?= M3LBSXNCVkeHUh?=
MHH-NB-11 NWLLc|NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT5VXJFUUN3ME2yMlcxOjl7IN88US=> NXK5WXN2W0GQR1XS
CHP-212 NUj4N|JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3voNmlEPTB;Mj64NlA6OSEQvF2= NHPrdoxUSU6JRWK=
DMS-273 MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rKcmlEPTB;Mj65NFIxPyEQvF2= NYTVWVZkW0GQR1XS
SF295 M1[2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzGTWM2OD1|LkCyOVk4KM7:TR?= Mn;JV2FPT0WU
NCI-H1563 NYC0TIhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzkbIhTUUN3ME2zMlE2ODB3IN88US=> M4q2SnNCVkeHUh?=
NCI-H446 NXXKd4Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PLN2lEPTB;Mz6yNlgxPSEQvF2= MXHTRW5ITVJ?
HCC1806 NUDV[IV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDHfohQUUN3ME2zMlI4PjV5IN88US=> NEDsd2FUSU6JRWK=
SF126 M4\XXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm5SZdKSzVyPUOuN|AxOTdizszN MmPuV2FPT0WU
SW982 NFrhXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S3fGlEPTB;Mz6zN|g4PSEQvF2= NXTtc4pEW0GQR1XS
ES8 NHTOOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;ZOpNKSzVyPUOuN|Q6QTlizszN MXLTRW5ITVJ?
SCC-4 NEn2R|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnxR|ZKSzVyPUOuOVA{QTZizszN M2OxT3NCVkeHUh?=
RPMI-8226 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\peFBJUUN3ME2zMlYzPjF4IN88US=> NWSwS|BFW0GQR1XS
EW-11 M3n0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjTTYR[UUN3ME2zMlY{ODJ{IN88US=> NWL2dGkzW0GQR1XS
COR-L105 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTNwNkOzN|Qh|ryP MXfTRW5ITVJ?
ES1 M1fT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\yTWM2OD1|LkizNFk1KM7:TR?= NE\1SoVUSU6JRWK=
KMOE-2 NF7xVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwOUG4NFgh|ryP NF75S4pUSU6JRWK=
ABC-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HUd2lEPTB;Mz65N|kyOSEQvF2= MX3TRW5ITVJ?
NCI-H526 NXjCb5dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTNwOUmxNlYh|ryP NWTxTWxNW0GQR1XS
HCC1395 NVLZNJFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f6O2lEPTB;Mz65PVQ5PCEQvF2= MV7TRW5ITVJ?
DU-145 Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPlemxKSzVyPUSuNVI5OjVizszN M4\xc3NCVkeHUh?=
JEG-3 NE\GNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfS[ZlKSzVyPUSuNVU6OTZizszN MUDTRW5ITVJ?
HCC1187 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXOTWM2OD12LkKxOVk4KM7:TR?= NHLOfFRUSU6JRWK=
LC-2-ad NXzVXVd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDEU5BRUUN3ME20MlIzOTd5IN88US=> NIj1ZYZUSU6JRWK=
ONS-76 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHHTlJKSzVyPUSuNlQyQTJizszN NHPZWWJUSU6JRWK=
CAL-27 MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfaUlFGUUN3ME20MlI1OzR2IN88US=> MXPTRW5ITVJ?
8-MG-BA MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTRwMk[2OVgh|ryP NFH6ZY9USU6JRWK=
HGC-27 NHPTelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;YTWM2OD12LkK5OlYh|ryP MUXTRW5ITVJ?
Hs-578-T Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPITWM2OD12LkOxOFY5KM7:TR?= MlfRV2FPT0WU
EW-1 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnsSnd7UUN3ME20MlU{ODF2IN88US=> MlzXV2FPT0WU
SW1573 M1X4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnROnFKSzVyPUSuOVUyPjNizszN NH;XVldUSU6JRWK=
SNU-423 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjp[HNKSzVyPUSuOlA4QSEQvF2= NWjKdmsxW0GQR1XS
HOS NYDoT25QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3ZWpBNUUN3ME20MlY6PzdizszN MVTTRW5ITVJ?
LB1047-RCC M2PEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLjSYJKSzVyPUSuPFE1OThizszN M1XWdXNCVkeHUh?=
ChaGo-K-1 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn32TWM2OD12Lki5NFQ5KM7:TR?= NUjydYRSW0GQR1XS
A3-KAW NIX6d|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\4XI1sUUN3ME20Mlk4OzV{IN88US=> NV[4ZoZMW0GQR1XS
CAS-1 NVu3OW1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPsR3lKSzVyPUSuPVk6ODhizszN NUm2W5NlW0GQR1XS
NBsusSR MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTTVGlKSzVyPUWuNFM2OTRizszN M{nBdnNCVkeHUh?=
KM12 M{D1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknHTWM2OD13LkK5PFI4KM7:TR?= M1\sW3NCVkeHUh?=
NCI-H1155 MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHscGhZUUN3ME21MlM5OTh3IN88US=> NH\NfWNUSU6JRWK=
EFM-19 NEXzVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Plb2lEPTB;NT60NVc{PyEQvF2= NFrMSWFUSU6JRWK=
D-392MG NHWyco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1SyRWlEPTB;NT61O|g1QSEQvF2= NILGSWNUSU6JRWK=
JVM-3 NHSx[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TL[2lEPTB;NT63NlMzPSEQvF2= M2fJbnNCVkeHUh?=
EW-16 M1e3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LvNGlEPTB;NT63OVU5OyEQvF2= NVfQeXI1W0GQR1XS
KARPAS-45 M2rYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTVwOESzNlUh|ryP NEXFVoZUSU6JRWK=
NCI-H28 NFyxRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrQTWM2OD13Lki3PVE5KM7:TR?= NHGxR5hUSU6JRWK=
COLO-829 NHHoc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvRUplJUUN3ME21MlkyPTB2IN88US=> NXTSfoROW0GQR1XS
KM-H2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLi[GVKSzVyPUWuPVI{QTVizszN NGnsU|dUSU6JRWK=
NCI-H82 NVzi[pBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TwemlEPTB;NT65Nlc4OSEQvF2= MnXRV2FPT0WU
OAW-42 MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTVwOUi4NlEh|ryP Mlu4V2FPT0WU
A704 NH:y[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjreJRvUUN3ME22MlExPTd2IN88US=> MnzaV2FPT0WU
NCI-H1048 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK0dpFKSzVyPU[uNVA2QTlizszN M4DWS3NCVkeHUh?=
LOXIMVI NH;r[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPTXHZKSzVyPU[uNVEzPDhizszN MUDTRW5ITVJ?
MKN45 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nuPGlEPTB;Nj6yOlAyPiEQvF2= NHzNTVhUSU6JRWK=
D-502MG M{jZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fCdWlEPTB;Nj6yPFg2PyEQvF2= MXXTRW5ITVJ?
HUTU-80 M3LJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PSWGlEPTB;Nj60NVY5QCEQvF2= NWq3dFhkW0GQR1XS
S-117 NYfhN4VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDyXpRHUUN3ME22MlUxOjZ5IN88US=> M{HCS3NCVkeHUh?=
HCC1569 NHr4e5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXqySYY{UUN3ME22MlU{PzN5IN88US=> NV:5e5RIW0GQR1XS
J-RT3-T3-5 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nzT2lEPTB;Nj61OFU4OiEQvF2= MUTTRW5ITVJ?
OC-314 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG4TWM2OD14LkmxNVU6KM7:TR?= M2H1enNCVkeHUh?=
SNU-449 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HKTWlEPTB;Nz6wNVA4OiEQvF2= NH[wenNUSU6JRWK=
NCI-H720 M2LQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[3bldKSzVyPUeuNVk{PDVizszN NUjB[Ix6W0GQR1XS
KP-N-YS MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K0OGlEPTB;Nz6yNFczKM7:TR?= MX3TRW5ITVJ?
IGROV-1 NXjYc4NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTUR|dWUUN3ME23MlMzOzh4IN88US=> NH65UnhUSU6JRWK=
SK-PN-DW NWrKOIpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfic3lRUUN3ME23MlQ5OTVizszN NHfPeG1USU6JRWK=
HCC1419 NXLjOGptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVWweJQzUUN3ME23MlU{KM7:TR?= MUPTRW5ITVJ?
HAL-01 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[zfHFYUUN3ME23MlYxPjR2IN88US=> MlfuV2FPT0WU
HCC2998 M2OwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu5W2QxUUN3ME23MlYxPzR|IN88US=> M1zCfHNCVkeHUh?=
SK-N-FI MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki3TWM2OD15Lk[zNFM{KM7:TR?= MVTTRW5ITVJ?
GI-ME-N NWXmd445T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf5TWM2OD15Lk[0PVM1KM7:TR?= M4rN[HNCVkeHUh?=
SW1088 M2DlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml32TWM2OD15Lk[1PFI3KM7:TR?= NETrZW5USU6JRWK=
IA-LM M{L5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnYcWlKSzVyPUeuOlg3OTNizszN MVTTRW5ITVJ?
SK-NEP-1 Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTdwNkm2NUDPxE1? MYPTRW5ITVJ?
MDA-MB-415 MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jLfGlEPTB;Nz64PVE5PiEQvF2= MUXTRW5ITVJ?
COLO-800 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjPTWM2OD15Lkm0OFkzKM7:TR?= NGfEXFhUSU6JRWK=
NCI-H2228 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRThwMUW3PFMh|ryP NInPU5dUSU6JRWK=
D-423MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fjXmlEPTB;OD6yNVczKM7:TR?= MmHKV2FPT0WU
TE-1 NGPLNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Dv[mlEPTB;OD60OFMyPiEQvF2= MYPTRW5ITVJ?
NOS-1 NIL4TZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H3UGlEPTB;OD61NVU{PCEQvF2= M3e5enNCVkeHUh?=
8505C MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRThwNkS4NlQh|ryP NV2ydVZ7W0GQR1XS
HEC-1 NUeycVRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu4OYVKSzVyPUiuO|g1OzlizszN M3Xid3NCVkeHUh?=
TE-11 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRThwOUm1OVEh|ryP NEfZfYlUSU6JRWK=
CTB-1 NGL3eZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTlwMEG0N|Mh|ryP MVXTRW5ITVJ?
TGBC11TKB NFvUdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7aTWM2OD17LkCyNlQyKM7:TR?= NV;BcpJmW0GQR1XS
NB17 NXrmWXhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3Hem1EUUN3ME25MlE5QDdizszN M1;xOXNCVkeHUh?=
Becker MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXDTWM2OD17LkSxPVQ1KM7:TR?= NEHHPXhUSU6JRWK=
SN12C Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTlwNEWyN|Qh|ryP MnTOV2FPT0WU
COLO-320-HSR NWfEbmlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTlwNkCyN|ch|ryP MkHDV2FPT0WU
D-283MED NIf2bIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHxc2RKSzVyPUmuOlMxPzJizszN NYXLXHBJW0GQR1XS
D-263MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnocWtKSzVyPUmuPFM{QDRizszN M4LRb3NCVkeHUh?=
MEL-JUSO NEDnO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvRT|ZKSzVyPUmuPVAyOjdizszN MlTFV2FPT0WU
T98G NE\ufm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\wZ4hKSzVyPUmuPVAzODNizszN M37Yb3NCVkeHUh?=
HLE M2O0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfnN3NKSzVyPUmuPVA6ODlizszN NVH3XG53W0GQR1XS
Ca9-22 MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILzcGpKSzVyPUGwMlA3PjVizszN NIK1OFRUSU6JRWK=
OS-RC-2 NFXrXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFyLkGwOFUh|ryP MWXTRW5ITVJ?
T47D M3vvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFyLkG1OUDPxE1? NGLXV3pUSU6JRWK=
GI-1 M1\yUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFyLkO1N|Mh|ryP M2DDenNCVkeHUh?=
NUGC-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ZXmlEPTB;MUCuOFQxOiEQvF2= NVn3NGY1W0GQR1XS
MDA-MB-361 NUTocXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXwNJJKSzVyPUGwMlQ1OzJizszN MlftV2FPT0WU
SCC-15 NGjEOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoexTWM2OD1zMD60O|E5KM7:TR?= NUPNfmwzW0GQR1XS
KS-1 NHfWWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli4TWM2OD1zMD62N|AyKM7:TR?= MlXTV2FPT0WU
CAL-12T NVrzN2pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGraVINKSzVyPUGwMlY{PjFizszN Mnn3V2FPT0WU
OVCAR-4 M3zncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nPW2lEPTB;MUCuO|A3QCEQvF2= MmL1V2FPT0WU
HuP-T4 NELYNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELSNmVKSzVyPUGxMlA{OjhizszN MoXFV2FPT0WU
NCI-H358 NEez[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7OTWM2OD1zMT6yOlU4KM7:TR?= M2jDSnNCVkeHUh?=
HO-1-N-1 NEnzUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP6dFVTUUN3ME2xNU4{Ozl6IN88US=> MnizV2FPT0WU
NH-12 Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj0VmU{UUN3ME2xNU42Ozd6IN88US=> M4HoTnNCVkeHUh?=
MOLT-4 MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfWTWM2OD1zMT61PVg2KM7:TR?= NFS4OnlUSU6JRWK=
K-562 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD4TWM2OD1zMT63NlQ5KM7:TR?= NXjiSYJNW0GQR1XS
ES6 NY\2OIZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnJTWM2OD1zMT64OVgyKM7:TR?= NIrqc5RUSU6JRWK=
RO82-W-1 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFzLkmwOlQh|ryP NWnLdoxQW0GQR1XS
Ramos-2G6-4C10 M{flT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW3TWM2OD1zMT65N|Ih|ryP NX[1WWU5W0GQR1XS
23132-87 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XrdmlEPTB;MUKuNFgzOSEQvF2= NF7weIZUSU6JRWK=
A549 NIfhemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonxTWM2OD1zMj6zNlg2KM7:TR?= MnLpV2FPT0WU
NCI-H23 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vsZWlEPTB;MUKuOVAzPiEQvF2= MmrjV2FPT0WU
H9 M1fNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fBb2lEPTB;MUKuOVU4PyEQvF2= M{PS[XNCVkeHUh?=
LB771-HNC M1LLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGizeZhKSzVyPUGyMlc3PSEQvF2= NYOyd5JUW0GQR1XS
QIMR-WIL NX;xUWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvQVZoyUUN3ME2xNk45OjV6IN88US=> NH7kdYhUSU6JRWK=
HSC-3 NVzYblZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7ae|ZyUUN3ME2xNk46Ojd4IN88US=> M{DXTHNCVkeHUh?=
PFSK-1 Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF{Lkm1NFch|ryP NWmzN2RpW0GQR1XS
ETK-1 NV\EOXJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjYSnJKSzVyPUGzMlA4PzlizszN M4C5S3NCVkeHUh?=
SW1710 NVLjN2ptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjNSo1KSzVyPUGzMlM3PDFizszN M4\aNXNCVkeHUh?=
COLO-684 NFfxVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlmzTWM2OD1zMz60OVQyKM7:TR?= M1HHWXNCVkeHUh?=
RPMI-7951 NEfObYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF|LkWxN|Yh|ryP MojTV2FPT0WU
A101D MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnFc25HUUN3ME2xN{42OzR7IN88US=> Mmf5V2FPT0WU
KE-37 NEDN[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK1TWM2OD1zMz61PFg4KM7:TR?= MnHYV2FPT0WU
SiHa Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSwTWM2OD1zMz64N|Q3KM7:TR?= MUnTRW5ITVJ?
NCI-H226 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHJTYJKSzVyPUGzMlg5ODhizszN NF3Nc2lUSU6JRWK=
DB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF|Lkm5Nlgh|ryP MlXSV2FPT0WU
HT-1197 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILieVZKSzVyPUG0MlA5ODlizszN MmflV2FPT0WU
SBC-5 MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHVTWM2OD1zND6xN|YzKM7:TR?= MmLxV2FPT0WU
VMRC-RCZ NFLNNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF2LkW3O|Qh|ryP MX7TRW5ITVJ?
697 M1XLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF2Lk[yO{DPxE1? MmnXV2FPT0WU
OMC-1 M13HUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzlTWM2OD1zND63PFg5KM7:TR?= MWTTRW5ITVJ?
SKG-IIIa NEfpPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnwUlZlUUN3ME2xOE45ODBzIN88US=> NGjWT|BUSU6JRWK=
DOK M3T0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF2Lkm5N|Mh|ryP M3fuZnNCVkeHUh?=
NCI-H2029 NV62Now3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi5U2hsUUN3ME2xOU4{PjB{IN88US=> M4H3NXNCVkeHUh?=
NCI-H2009 MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH0TWM2OD1zNT61NFk2KM7:TR?= MXLTRW5ITVJ?
LK-2 NELDNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITVTYtKSzVyPUG1MlY1PDlizszN NFrJO2RUSU6JRWK=
NCI-H661 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;UdmlEPTB;MUWuPVA4PSEQvF2= MUnTRW5ITVJ?
GT3TKB NF\4UFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rJT2lEPTB;MU[uNFY4PiEQvF2= NI\BOGVUSU6JRWK=
GP5d MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4roOGlEPTB;MU[uN|QzKM7:TR?= MoqwV2FPT0WU
SK-MEL-2 NYnRdYxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfjTYhwUUN3ME2xOk41PDh3IN88US=> MnPkV2FPT0WU
SK-UT-1 Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLSTWM2OD1zNj61OlUh|ryP MlrLV2FPT0WU
NB7 NI[4emNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr5NIQ2UUN3ME2xOk43QTdzIN88US=> MlvvV2FPT0WU
NCI-H460 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfKTWM2OD1zNj63N|I3KM7:TR?= MUnTRW5ITVJ?
8305C NWqzRZBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTF4Lke4O|ch|ryP M{XuT3NCVkeHUh?=
CaR-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe4VIRZUUN3ME2xOk45OTFzIN88US=> NHfrZndUSU6JRWK=
D-247MG M4nlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrQTWM2OD1zNj64OlI2KM7:TR?= MlvhV2FPT0WU
LoVo NGTMT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjVfmFKSzVyPUG2Mlk1QDhizszN MoDCV2FPT0WU
NCI-H2405 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDUWZlKSzVyPUG3MlE6ODhizszN MnnmV2FPT0WU
AU565 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17PcWlEPTB;MUeuNlI2KM7:TR?= NFTiWFdUSU6JRWK=
OCI-AML2 M1jr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qyV2lEPTB;MUeuOVMyPyEQvF2= NUjpfm9jW0GQR1XS
22RV1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjnfmZKSzVyPUG3MlU5QDRizszN MUXTRW5ITVJ?
HT-144 M1OwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzKW5NVUUN3ME2xO{43PTl6IN88US=> M3W5NnNCVkeHUh?=
HuO9 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3KcYQzUUN3ME2xO{44ODNzIN88US=> MUPTRW5ITVJ?
Daoy MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf4V|NwUUN3ME2xO{44OTh2IN88US=> NXXoTldTW0GQR1XS
SJRH30 NGXNb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LOWWlEPTB;MUeuPFQ5QSEQvF2= MXrTRW5ITVJ?
CHL-1 M2rIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fVcmlEPTB;MUeuPVI1QSEQvF2= MoSwV2FPT0WU
J82 NEDO[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF5Lkm2N|Uh|ryP MoroV2FPT0WU
COR-L23 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknyTWM2OD1zOD6wNFEyKM7:TR?= MlXZV2FPT0WU
SNU-C2B M3y0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPJTWM2OD1zOD6yNlc3KM7:TR?= MVjTRW5ITVJ?
NCI-H1770 NETVfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjE[XBFUUN3ME2xPE41PjF3IN88US=> NULn[YxDW0GQR1XS
MHH-PREB-1 Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF6LkW2PVch|ryP NES0VYxUSU6JRWK=
ES3 NUS4Um8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPHTWM2OD1zOD61PFg{KM7:TR?= M1\jWXNCVkeHUh?=
MDA-MB-231 M1TjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF6Lk[1NFIh|ryP MVvTRW5ITVJ?
MN-60 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn21TWM2OD1zOT6wOVkzKM7:TR?= NX;SS2pDW0GQR1XS
EPLC-272H NX6zRVZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;xTWM2OD1zOT6zO|A5KM7:TR?= M{LHV3NCVkeHUh?=
SW948 Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLyWItYUUN3ME2xPU4{QTN2IN88US=> NW\DdnpYW0GQR1XS
MOLT-13 NUW2OZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF7LkS1OFYh|ryP NIPvfIVUSU6JRWK=
HL-60 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPVTWM2OD1{MD6yNVQyKM7:TR?= NYPadZFoW0GQR1XS
CP50-MEL-B M4LVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTCV5lKSzVyPUKwMlQ4PDhizszN NWq0TYc6W0GQR1XS
NTERA-S-cl-D1 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnITWM2OD1{MD60PVc5KM7:TR?= NUjxcmhUW0GQR1XS
KINGS-1 NWLFdphCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJyLke5Olch|ryP NIq5U49USU6JRWK=
DOHH-2 NUfTPYd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\ZeWJKSzVyPUKwMlkxPiEQvF2= NYrqV3U5W0GQR1XS
BB65-RCC NUHi[GZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HwRmlEPTB;MkCuPVI5PSEQvF2= M4PXR3NCVkeHUh?=
NB12 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJzLkCzPVQh|ryP MoTmV2FPT0WU
KY821 NXLz[VhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3MTWM2OD1{MT61PFIh|ryP MUDTRW5ITVJ?
PSN1 M{XIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJzLk[0OVMh|ryP NVzLWFF6W0GQR1XS
EGI-1 NGCwOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHmUWhKSzVyPUKxMlc1PTRizszN M2e0bnNCVkeHUh?=
CTV-1 M4rPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DRfGlEPTB;MkKuN|A{OSEQvF2= NWrUfoV{W0GQR1XS
TI-73 M2LRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\QVYdGUUN3ME2yNk4{PDl6IN88US=> MXjTRW5ITVJ?
LCLC-103H NYr2NWtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjxNYlKSzVyPUKyMlQ4PTJizszN M1;xTHNCVkeHUh?=
D-542MG NGXDV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJ{LkW1OVgh|ryP NYXNUlhVW0GQR1XS
ATN-1 NXfhUpQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ{Lk[0N|kh|ryP NG[3W5FUSU6JRWK=
SK-MEL-1 NYrHUppZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJ{LkizOlgh|ryP MlX5V2FPT0WU
HDLM-2 NGTrcmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r2TmlEPTB;MkOuNVQ4QCEQvF2= NIjkWXRUSU6JRWK=
UM-UC-3 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjKPFJuUUN3ME2yN{4yQTR2IN88US=> NFvQVVVUSU6JRWK=
NCI-H1573 NFTSW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfmUmdNUUN3ME2yN{41PjhzIN88US=> NIXpXINUSU6JRWK=
NCI-H520 MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ISFV1UUN3ME2yN{41QTR6IN88US=> NXTSemFzW0GQR1XS
ESS-1 M{Pye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLMTWM2OD1{Mz64NFU6KM7:TR?= NYXYc3cyW0GQR1XS
COR-L88 MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPVTWM2OD1{Mz65OFc2KM7:TR?= MX7TRW5ITVJ?
TGBC24TKB NISz[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnLVXZvUUN3ME2yOE4xOzF{IN88US=> NWPXbZZNW0GQR1XS
HCC1937 NILvRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P0TmlEPTB;MkSuNUDPxE1? NWTRTHdWW0GQR1XS
RS4-11 M{jSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjPTopLUUN3ME2yOE4yPDJizszN NWPBVm9FW0GQR1XS
HCC38 NH3hOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK2U2ZKSzVyPUK0MlI{QTRizszN M4C4ZXNCVkeHUh?=
RPMI-2650 M1nhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm1TWM2OD1{ND62NVYzKM7:TR?= Mn;sV2FPT0WU
P12-ICHIKAWA NXnabY5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLmeJVbUUN3ME2yOE43OjV6IN88US=> MULTRW5ITVJ?
YAPC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXSTWM2OD1{ND64NlE1KM7:TR?= MVTTRW5ITVJ?
NB13 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq0NlZKUUN3ME2yOU4zPjFzIN88US=> NH\OXppUSU6JRWK=
SK-N-AS MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJ3Lki1PFQh|ryP MkHZV2FPT0WU
SK-N-DZ MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJ4LkC0PUDPxE1? NETxcnNUSU6JRWK=
LS-411N MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:wWYVJUUN3ME2yOk4zODN6IN88US=> M2G1S3NCVkeHUh?=
NCI-H810 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PZSmlEPTB;Mk[uN|EyOiEQvF2= MWXTRW5ITVJ?
NCI-SNU-1 MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq1TWM2OD1{Nj61OFU1KM7:TR?= M{\wenNCVkeHUh?=
HH MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ4LkW1Nlkh|ryP MlvKV2FPT0WU
U-2-OS MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn6SJZKSzVyPUK2Mlc{QDJizszN M2DzeXNCVkeHUh?=
SF539 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXNdYdKSzVyPUK2MlgxOThizszN NFTkVmVUSU6JRWK=
NCI-H2052 M{i3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG1epJMUUN3ME2yO{4xQDZizszN NFHzeHdUSU6JRWK=
A673 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETM[WFKSzVyPUK3MlIyODJizszN NX;wcmhwW0GQR1XS
WM-115 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH21S3NKSzVyPUK3Mlc4PjdizszN M3zSdXNCVkeHUh?=
SW48 NF\MV|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXCU2FFUUN3ME2yO{45ODB3IN88US=> MWfTRW5ITVJ?
NOMO-1 NV[4V2tQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJ5Lki1N|Ih|ryP MnvqV2FPT0WU
PC-3 M1PVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjzTm9KSzVyPUK3Mlg6PDFizszN M3PaSnNCVkeHUh?=
UMC-11 M{W5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPITWM2OD1{Nz65N|Q{KM7:TR?= MXfTRW5ITVJ?
U-118-MG NHXxOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJ6LkCxNlMh|ryP NVXPbot[W0GQR1XS
NCI-H2452 M4XoVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELnc3JKSzVyPUK4MlA5OjJizszN MlPZV2FPT0WU
CAMA-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ6Lki1OlQh|ryP NE[4cphUSU6JRWK=
MC-IXC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfxbXlKSzVyPUK5MlI{PjZizszN MojoV2FPT0WU
ES4 NXvFN2FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ7LkOxO|Ih|ryP MmK3V2FPT0WU
BHT-101 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLK[2xKSzVyPUK5MlMzOSEQvF2= Ml7NV2FPT0WU
KP-4 NX7MNXJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXNU4NxUUN3ME2yPU42OTZizszN NF3ySYRUSU6JRWK=
CAL-54 NWToN4NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO3V2VnUUN3ME2yPU42PDR3IN88US=> Mnv3V2FPT0WU
5637 MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnaNFd2UUN3ME2yPU43PDJzIN88US=> NFXsZVZUSU6JRWK=
MOLT-16 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nLS2lEPTB;MkmuO|I3QSEQvF2= NYXmcFVqW0GQR1XS
Ca-Ski MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe1VG92UUN3ME2yPU46PDZizszN NFH4e5ZUSU6JRWK=
AsPC-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHwO2xNUUN3ME2zNE4xOjF{IN88US=> MWHTRW5ITVJ?
MSTO-211H NV;lRolDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ToSGlEPTB;M{CuNVUh|ryP NHrEdIhUSU6JRWK=
L-428 MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2KzTGlEPTB;M{CuOFA2KM7:TR?= NUL2[|lwW0GQR1XS
SW1463 M1XRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf5O4UyUUN3ME2zNE42Ozh|IN88US=> MXnTRW5ITVJ?
NCI-H1648 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xac2lEPTB;M{CuOVU4PCEQvF2= MXfTRW5ITVJ?
CAKI-1 NWTlUnQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNyLke3NFIh|ryP M17Rd3NCVkeHUh?=
YKG-1 NWXvboE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLRPVhKSzVyPUOxMlAzPjNizszN NF7n[FZUSU6JRWK=
A2058 M3\qU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknJTWM2OD1|MT6xNVY1KM7:TR?= MUfTRW5ITVJ?
A375 NUTt[m9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS0TXdYUUN3ME2zNU4yPjl4IN88US=> NXHiVpV5W0GQR1XS
SNB75 NXzZXmFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;ofGlEPTB;M{GuNlQ{PSEQvF2= NVPJOms2W0GQR1XS
SK-HEP-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Lx[WlEPTB;M{GuOFI4OSEQvF2= NFPubWtUSU6JRWK=
ME-180 NUnnUGRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jIZ2lEPTB;M{GuOlU1OiEQvF2= NUnMWYN4W0GQR1XS
NCI-H209 M17DO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrB[lFKUUN3ME2zNU45OjR5IN88US=> MYTTRW5ITVJ?
HC-1 NEXNdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjWTWM2OD1|Mj6xOFQ3KM7:TR?= NYjzOXF3W0GQR1XS
LB373-MEL-D NUL5N41QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLiXGNGUUN3ME2zNk4yQTdzIN88US=> M3LjRnNCVkeHUh?=
SNU-387 M2fiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXXTWM2OD1|Mj6zNVkyKM7:TR?= MlSwV2FPT0WU
C32 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTN{LkOzOVMh|ryP M1XzcHNCVkeHUh?=
EW-13 NYPKeZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD2WHp1UUN3ME2zNk46PDB6IN88US=> NELtemhUSU6JRWK=
BFTC-905 NH3uTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzqTWM2OD1|Mz61NVM3KM7:TR?= M4nHc3NCVkeHUh?=
NCI-H1299 NGHlSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTN|LkW2NlEh|ryP NEnsd4NUSU6JRWK=
LU-135 NGK3O21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTN|LkiwNUDPxE1? NHzUPVJUSU6JRWK=
NCI-H2122 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTN|Lkm5OlYh|ryP MnPqV2FPT0WU
SK-LMS-1 M2LpXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;FdGllUUN3ME2zOE41OTB5IN88US=> MXjTRW5ITVJ?
LNCaP-Clone-FGC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLUNnNKSzVyPUO0Mlg2OTVizszN MofaV2FPT0WU
NCI-H1092 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPJTWM2OD1|NT6yO|Q4KM7:TR?= NVn1Wmd5W0GQR1XS
MS-1 NYnie3RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHOO4ljUUN3ME2zOU4{ODN6IN88US=> MYDTRW5ITVJ?
KYSE-510 NXXsOlAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPrcXhKSzVyPUO1MlUxPDJizszN MWfTRW5ITVJ?
NCI-H1793 Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Ozc2lEPTB;M{WuOlU1PSEQvF2= MnjwV2FPT0WU
MIA-PaCa-2 NEPrSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PnRmlEPTB;M{[uNFQ6PiEQvF2= NYH6fYVnW0GQR1XS
EW-22 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjmTWM2OD1|Nj60NFczKM7:TR?= MXLTRW5ITVJ?
IGR-1 NVi0VG5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXTTWM2OD1|Nj64NVg1KM7:TR?= NUe2UZhiW0GQR1XS
HT-1080 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG3TWM2OD1|Nz6xNlUh|ryP NImzVVVUSU6JRWK=
M14 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfFTWM2OD1|Nz6xOlQzKM7:TR?= M33venNCVkeHUh?=
786-0 NHLBVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnpdoNKSzVyPUO3MlI4QTRizszN MoTxV2FPT0WU
MZ2-MEL M3XNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4CycWlEPTB;M{euOFUxOSEQvF2= M4HkT3NCVkeHUh?=
NCI-H510A MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTN5Lkm0NVIh|ryP NGiyVVFUSU6JRWK=
LAN-6 NGHvXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXOTWM2OD1|Nz65OVgzKM7:TR?= NV3G[VdwW0GQR1XS
SW620 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW4TWM2OD1|OD60PVc1KM7:TR?= NE[5PIRUSU6JRWK=
LB2241-RCC MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTN7LkiyNFUh|ryP MX7TRW5ITVJ?
Detroit562 NVTFeWc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHubmZKSzVyPUSwMlEzPjhizszN MlTnV2FPT0WU
HN NEj1c3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTRyLkG3PFIh|ryP NH;JSnlUSU6JRWK=
HCT-15 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rvNWlEPTB;NECuOVkxPyEQvF2= NHG5b|NUSU6JRWK=
C2BBe1 NH;6WW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TBXWlEPTB;NECuPVE2PyEQvF2= NGLP[o5USU6JRWK=
A498 MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTRzLkOwNVUh|ryP NHzUUohUSU6JRWK=
SK-MEL-24 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTRzLkS3NlUh|ryP MXLTRW5ITVJ?
OVCAR-5 NFvOfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jnUGlEPTB;NEGuO|c3PyEQvF2= Mom4V2FPT0WU
NCI-H1792 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnYNHdvUUN3ME20NU46QDJzIN88US=> MWfTRW5ITVJ?
KOSC-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO3cm1GUUN3ME20Nk4zPjl7IN88US=> MmXEV2FPT0WU
Mo-T MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm1VWZJUUN3ME20Nk45QTV6IN88US=> MYrTRW5ITVJ?
CFPAC-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjH[ppKSzVyPUSzMlQ6PDRizszN MmjMV2FPT0WU
CAL-51 NITZbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTR|LkW2NFUh|ryP M1nGXXNCVkeHUh?=
RH-18 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTR|LkiwOUDPxE1? MoTXV2FPT0WU
EC-GI-10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;YR3NKSzVyPUSzMlg{PDdizszN MofBV2FPT0WU
HSC-2 M3LrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTR2LkCwPUDPxE1? NV\XNWIyW0GQR1XS
ML-2 NV3DNoVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjL[G5KSzVyPUS1MlI3OjFizszN MlTCV2FPT0WU
KNS-81-FD M1XGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPzUoJkUUN3ME20OU44OzZ3IN88US=> MmXJV2FPT0WU
NB6 NUj2T2ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDmVWZKSzVyPUS2MlEyOSEQvF2= NFfZUpBUSU6JRWK=
MCF7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv3TWM2OD12Nj61OVM{KM7:TR?= NVK3cnVsW0GQR1XS
P30-OHK NVjaeVBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGwTWM2OD12Nj64NVE4KM7:TR?= NWPiSXZSW0GQR1XS
BPH-1 NIiwWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LEbmlEPTB;NE[uPVgxPSEQvF2= M1XXO3NCVkeHUh?=
U251 NYf3OWZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTR4Lkm5OEDPxE1? M1jnZXNCVkeHUh?=
MKN1 NWDRNZNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTR5LkWxN|ch|ryP MkGxV2FPT0WU
A431 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm3V4lKSzVyPUS3Mlg{OzhizszN NE\TSGRUSU6JRWK=
C8166 M2nFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHHOYFKSzVyPUS5MlIxOzlizszN NVrkWXpyW0GQR1XS
HEL M2C1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT6e5hKSzVyPUS5MlQxPjRizszN NUPhR|U4W0GQR1XS
RMG-I MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3aNmxEUUN3ME20PU41PDR2IN88US=> NGrDe5RUSU6JRWK=
CAL-72 NUnqVXg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTw[FZtUUN3ME20PU43ODd3IN88US=> MmrIV2FPT0WU
SW962 NUnScpNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjKTWM2OD12OT65N|MzKM7:TR?= M3KzN3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
0.5% CMC
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer June 2017 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer September 2016 Phase 1|Phase 2
NCT02859012 Recruiting Recurrent ACC, metastaticACC, Unreaectable ACC Seoul National University Hospital September 2016 Phase 2
NCT02853331 Recruiting Renal Cell Carcinoma Merck Sharp & Dohme Corp. September 2016 Phase 3
NCT02762513 Recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center|National Comprehensive Cancer Network August 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

Related Antibodies

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID